Alligator Bioscience’s rights issue is registered – conversion of BTU into shares and warrants
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience carries out a directed issue of units to guarantors and a directed issue of warrants to Fenja Capital in connection with the completed rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience announces final outcome in rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience announces preliminary outcome in rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience Successfully Completes End of Phase 2 Interaction with FDA For Mitazalimab
FDA feedback validates the clinical development strategy and Phase 3 design FDA feedback confirms that the toxicology package is adequate fo ...
Change in number of shares and votes in Alligator Bioscience
During the month of January, the number of shares and votes in Alligator Bioscience AB has changed as a result of the exercise of warrants s ...
Alligator Bioscience Announces Publication of Clinical Data for ATOR-1017 (evunzekibart) in the Journal for ImmunoTherapy of Cancer
Publication validates encouraging clinical safety and tolerability in this first-in-human trial Data show early signs of clinical efficacy i ...
The subscription period in Alligator Bioscience’s rights issue begins today
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience Reports Incremental Overall Survival Benefit of mitazalimab combined with mFOLFIRINOX based on Literature-based Indirect Comparison of Outcomes
Indirect Comparison shows significant improvement of OS of mitazalimab + mFOLFIRINOX, compared to known FOLFIRINOX and NALIRIFOX outcomes Th ...